These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 33713301

  • 21. Effect of epalrestat, an aldose reductase inhibitor, on the generation of oxygen-derived free radicals in neutrophils from streptozotocin-induced diabetic rats.
    Kashima K, Sato N, Sato K, Shimizu H, Mori M.
    Endocrinology; 1998 Aug; 139(8):3404-8. PubMed ID: 9681489
    [Abstract] [Full Text] [Related]

  • 22. Neuroprotection by the pyridoindole stobadine: a minireview.
    Stolc S, Vlkolinský R, Pavlásek J.
    Brain Res Bull; 1997 Aug; 42(5):335-40. PubMed ID: 9092873
    [Abstract] [Full Text] [Related]

  • 23. Carboxymethylated tetrahydropyridoindoles as aldose reductase inhibitors: in vitro selectivity study in intact rat erythrocytes in relation to glycolytic pathway.
    Juskova M, Snirc V, Gajdosikova A, Gajdosik A, Krizanova L, Stefek M.
    Gen Physiol Biophys; 2009 Dec; 28(4):325-30. PubMed ID: 20097954
    [Abstract] [Full Text] [Related]

  • 24. The aldose reductase inhibitor epalrestat exerts nephritic protection on diabetic nephropathy in db/db mice through metabolic modulation.
    He J, Gao HX, Yang N, Zhu XD, Sun RB, Xie Y, Zeng CH, Zhang JW, Wang JK, Ding F, Aa JY, Wang GJ.
    Acta Pharmacol Sin; 2019 Jan; 40(1):86-97. PubMed ID: 29930278
    [Abstract] [Full Text] [Related]

  • 25. Long-term clinical effects of epalrestat, an aldose reductase inhibitor, on progression of diabetic neuropathy and other microvascular complications: multivariate epidemiological analysis based on patient background factors and severity of diabetic neuropathy.
    Hotta N, Kawamori R, Fukuda M, Shigeta Y, Aldose Reductase Inhibitor-Diabetes Complications Trial Study Group.
    Diabet Med; 2012 Dec; 29(12):1529-33. PubMed ID: 22507139
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Standardized extracts of flavonoids increase the viability of PC12 cells treated with hydrogen peroxide: effects on oxidative injury.
    Horáková L, Licht A, Sandig G, Jakstadt M, Duracková Z, Grune T.
    Arch Toxicol; 2003 Jan; 77(1):22-9. PubMed ID: 12491037
    [Abstract] [Full Text] [Related]

  • 31. Aldose reductase inhibitor improves insulin-mediated glucose uptake and prevents migration of human coronary artery smooth muscle cells induced by high glucose.
    Yasunari K, Kohno M, Kano H, Minami M, Yoshikawa J.
    Hypertension; 2000 May; 35(5):1092-8. PubMed ID: 10818070
    [Abstract] [Full Text] [Related]

  • 32. IMM-H004, a Novel Coumarin Derivative Compound, Inhibits H2O2-Induced Neurotoxicity via Antioxidant and Antiapoptosis in PC12 Cells.
    Song XY, Hu JF, Wu DH, Ji HJ, Chen NH.
    J Stroke Cerebrovasc Dis; 2018 Dec; 27(12):3396-3403. PubMed ID: 30243729
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. 6,7-Dihydroxy-4-phenylcoumarin as inhibitor of aldose reductase 2.
    Kato A, Kobayashi K, Narukawa K, Minoshima Y, Adachi I, Hirono S, Nash RJ.
    Bioorg Med Chem Lett; 2010 Oct 01; 20(19):5630-3. PubMed ID: 20805028
    [Abstract] [Full Text] [Related]

  • 35. Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling.
    Gu J, Wang JJ, Yan J, Cui CF, Wu WH, Li L, Wang ZS, Yu M, Gao N, Liu L, Ouyang DS.
    J Ethnopharmacol; 2011 Jan 07; 133(1):6-13. PubMed ID: 20817083
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Updates on Aldose Reductase Inhibitors for Management of Diabetic Complications and Non-diabetic Diseases.
    Grewal AS, Bhardwaj S, Pandita D, Lather V, Sekhon BS.
    Mini Rev Med Chem; 2016 Jan 07; 16(2):120-62. PubMed ID: 26349493
    [Abstract] [Full Text] [Related]

  • 38. Protective effect of an aldose reductase inhibitor against bone loss in galactose-fed rats: possible involvement of the polyol pathway in bone metabolism.
    Inaba M, Terada M, Nishizawa Y, Shioi A, Ishimura E, Otani S, Morii H.
    Metabolism; 1999 Jul 07; 48(7):904-9. PubMed ID: 10421234
    [Abstract] [Full Text] [Related]

  • 39. Development of the new group of indole-derived neuroprotective drugs affecting oxidative stress.
    Stolc S, Snirc V, Májeková M, Gáspárová Z, Gajdosíková A, Stvrtina S.
    Cell Mol Neurobiol; 2006 Jul 07; 26(7-8):1495-504. PubMed ID: 16705480
    [Abstract] [Full Text] [Related]

  • 40. Aldose reductase structures: implications for mechanism and inhibition.
    El-Kabbani O, Ruiz F, Darmanin C, Chung RP.
    Cell Mol Life Sci; 2004 Apr 07; 61(7-8):750-62. PubMed ID: 15095000
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 15.